ENDRA Life Sciences Inc (NASDAQ:NDRA) — Market Cap & Net Worth
Market Cap & Net Worth: ENDRA Life Sciences Inc (NDRA)
ENDRA Life Sciences Inc (NASDAQ:NDRA) has a market capitalization of $8.16 Million ($8.16 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27536 globally and #5617 in its home market, demonstrating a 9.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENDRA Life Sciences Inc's stock price $4.69 by its total outstanding shares 1848464 (1.85 Million). Review ENDRA Life Sciences Inc balance sheet liabilities to assess the company's total debt and financial obligations.
ENDRA Life Sciences Inc Market Cap History: 2017 to 2026
ENDRA Life Sciences Inc's market capitalization history from 2017 to 2026. Data shows change from $15.72 Billion to $8.67 Million (-55.61% CAGR).
Index Memberships
ENDRA Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #795 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2567 of 3165 |
Weight: ENDRA Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ENDRA Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENDRA Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
785911.56x
ENDRA Life Sciences Inc's market cap is 785911.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $15.72 Billion | $351.62K | -$5.38 Million | 44713.23x | N/A |
| 2018 | $4.85 Billion | $6.17K | -$9.80 Million | 785911.56x | N/A |
Competitor Companies of NDRA by Market Capitalization
Companies near ENDRA Life Sciences Inc in the global market cap rankings as of June 17, 2026.
Key companies related to ENDRA Life Sciences Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
ENDRA Life Sciences Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, ENDRA Life Sciences Inc's market cap moved from $15.72 Billion to $ 8.67 Million, with a yearly change of -55.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.67 Million | +3.53% |
| 2025 | $8.37 Million | -27.64% |
| 2024 | $11.57 Million | -99.83% |
| 2023 | $6.86 Billion | -47.91% |
| 2022 | $13.17 Billion | +488.32% |
| 2021 | $2.24 Billion | -7.76% |
| 2020 | $2.43 Billion | -55.36% |
| 2019 | $5.43 Billion | +12.00% |
| 2018 | $4.85 Billion | -69.14% |
| 2017 | $15.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of ENDRA Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.16 Million USD |
| MoneyControl | $8.16 Million USD |
| MarketWatch | $8.16 Million USD |
| marketcap.company | $8.16 Million USD |
| Reuters | $8.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fa… Read more